These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21180652)

  • 1. Molecule of the Month. TAK-875.
    Drug News Perspect; 2010 Dec; 23(10):667. PubMed ID: 21180652
    [No Abstract]   [Full Text] [Related]  

  • 2. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
    Mohammad S
    Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Vink G; Nebel JC; Wren SP
    Future Med Chem; 2021 Apr; 13(8):691-700. PubMed ID: 33715419
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.
    Naik H; Vakilynejad M; Wu J; Viswanathan P; Dote N; Higuchi T; Leifke E
    J Clin Pharmacol; 2012 Jul; 52(7):1007-16. PubMed ID: 21610201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
    Choi YJ; Shin D; Lee JY
    Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
    Li Z; Zhou Z; Zhang L
    Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
    Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
    Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel orally bioavailable GPR40 agonists.
    Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
    Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
    J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
    Burant CF
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for GPR40 allosteric agonism and incretin stimulation.
    Ho JD; Chau B; Rodgers L; Lu F; Wilbur KL; Otto KA; Chen Y; Song M; Riley JP; Yang HC; Reynolds NA; Kahl SD; Lewis AP; Groshong C; Madsen RE; Conners K; Lineswala JP; Gheyi T; Saflor MD; Lee MR; Benach J; Baker KA; Montrose-Rafizadeh C; Genin MJ; Miller AR; Hamdouchi C
    Nat Commun; 2018 Apr; 9(1):1645. PubMed ID: 29695780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
    Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
    Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U; Kowalski TJ
    Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
    Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
    Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
    J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
    Kaku K
    Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.